Cogent Biosciences, INC. 8-K Filing
Ticker: COGT · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1622229
| Field | Detail |
|---|---|
| Company | Cogent Biosciences, INC. (COGT) |
| Form Type | 8-K |
| Filed Date | Dec 8, 2025 |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Cogent Biosciences, INC. (ticker: COGT) to the SEC on Dec 8, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ange on which registered Common stock, $0.001 Par Value COGT The Nasdaq Global Se).
How long is this filing?
Cogent Biosciences, INC.'s 8-K filing is 6 pages with approximately 1,698 words. Estimated reading time is 7 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,698 words · 7 min read · ~6 pages · Grade level 11.9 · Accepted 2025-12-08 16:05:52
Key Financial Figures
- $0.001 — ange on which registered Common stock, $0.001 Par Value COGT The Nasdaq Global Se
Filing Documents
- d81277d8k.htm (8-K) — 49KB
- 0001193125-25-311217.txt ( ) — 165KB
- cogt-20251206.xsd (EX-101.SCH) — 3KB
- cogt-20251206_lab.xml (EX-101.LAB) — 18KB
- cogt-20251206_pre.xml (EX-101.PRE) — 11KB
- d81277d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: plans to submit an NDA to the FDA for bezuclastinib in AdvSM during the first half of 2026 and plans to present detailed results from the APEX trial at an upcoming scientific meeting in the first half of 2026. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on the Company's current beliefs, expectations and assumptions regarding the future of the Company's business, future plans and strategies, the Company's clinical results, the rate of enrollment in the Company's clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. The Company may not actually achieve the forecasts or milestones disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings made with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Neither the Company's, nor its affiliates,
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 8, 2025 COGENT BIOSCIENCES, INC. By: /s/ Evan Kearns Evan Kearns Chief Legal Officer